Small caps round-up: Transense Tech, Hightex, Verona Pharma
Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indonesian distributor, AutoRFID Solutions.
Transense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indonesian distributor, AutoRFID Solutions.
The system will be installed as part of a pilot scheme on three of the 168 vehicles at the ADARO mine in Indonesia, one of AutoRFID's clients. Graham Storey, Chief Executive Officer of Transense, said it is "very encouraging that our success in South Africa has triggered this order in what is a new territory for us".
Hightex Group, a systems engineering company, has been selected, along with its Brazilian construction partner SEPA, to engineer and install the membrane structure of the roof of the Beira-Rio Stadium in Porto Alegre, a 2014 FIFA World Cup venue. The deal, which has a value in the region of €10m, marks the firm's second contract win in Brazil. The stadium is the fifth largest in Brazil, and will accommodate around 50,000 spectators. Work will begin immediately and is due to be completed in 2013.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Verona Pharma, a drug discovery company, has been granted a new patent for its lead drug candidate, RPL554, in the US. The product is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company is currently carrying out clinical trials of the drug to further characterise its bronchodilator and anti-inflammatory effects.
NR
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Do you qualify for the Winter Fuel Payment if you live abroad?
The Winter Fuel Payment will be means tested for expats living in Europe, in line with the new rules impacting those in the UK. But a quirk in the system means not all countries are eligible.
By Katie Williams Published
-
What the Employment Rights Bill means for your job
New workplace reforms are set to give employees new rights to benefits and flexible working
By Marc Shoffman Published